Hepatitis A Hospitalizations Down From 2002 to 2011

This article originally appeared here.
Share this content:
Hepatitis A Hospitalizations Down From 2002 to 2011
Hepatitis A Hospitalizations Down From 2002 to 2011

THURSDAY, Jan. 29, 2015 (HealthDay News) -- From 2002 to 2011 there was a decrease in the rate of hospitalizations for hepatitis A, according to a study published in the February issue of Hepatology.

Melissa G. Collier, M.D., from the U.S. Centers for Disease Control and Prevention in Atlanta, and colleagues describe changes in primary hepatitis A hospitalization rates in the United States from 2002 to 2011. The effect of secondary diagnoses on hospitalization length of stay was also examined.

The researchers found that during 2002 to 2011 there was a decrease in the rates of hospitalization for hepatitis A as a principal diagnosis, from 0.72/100,000 to 0.29/100,000 (P < 0.0001); there was also an increase in the mean age of those hospitalized from 37.6 to 45.5 years (P < 0.0001). There was an increase in the percentage of hepatitis A hospitalizations covered by Medicare, from 12.4 to 22.7 percent (P < 0.0001). There were increases in secondary comorbid discharge diagnoses, including liver disease, hypertension, ischemic heart disease, disorders of lipid metabolism, and chronic kidney disease. Over time, there were no changes in length of stay or in-hospital death from hepatitis A, but longer hospitalizations were seen for those with liver disease.

"Hospitalization rates for hepatitis A illness have declined significantly from 2002 to 2011, but the characteristics of the hospitalized population also changed," the authors write. "Hepatitis A disease and resulting hospitalizations could be prevented through adult vaccination."

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Permits Marketing of Brain Stimulation Device for OCD

FDA Permits Marketing of Brain Stimulation Device for ...

FDA previously approved transcranial magnetic stimulation for major depression, certain migraines

Comments Open on End of NIH Review for Gene Therapy Studies

Comments Open on End of NIH Review for ...

NIH oversight panel no longer plans to review all applications for gene therapy experiments

U.S. Measles Outbreak Hits 107 Cases in 21 States, D.C.

U.S. Measles Outbreak Hits 107 Cases in 21 ...

Outbreak on track to exceed last year's; most of the people who got measles weren't vaccinated

is free, fast, and customized just for you!




Already a member?

Sign In Now »